The use of PCA3 in the diagnosis of prostate cancer (original) (raw)

• Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
  Article Google Scholar
• Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581–592 (2007).
  Article CAS Google Scholar
• Roddam, A. W. et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur. Urol. 4, 386–399 (2005).
  Article Google Scholar
• Hessels, D. et al. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev. Mol. Diagn. 4, 513–526 (2004).
  Article CAS PubMed Google Scholar
• Hessels, D. et al. Molecular Diagnostics in Prostate Cancer. EAU Update Series 3, 200–213 (2005).
  Article Google Scholar
• Bussemakers, M. J. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975–5979 (1999).
  CAS PubMed Google Scholar
• de Kok, J. B. et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695–2698 (2002).
  CAS PubMed Google Scholar
• Hessels, D. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8–15 (2003).
  Article CAS PubMed Google Scholar
• Schalken, J. A. et al. New targets for therapy in prostate cancer: differential display code 3 (DD3 [PCA3]), a highly prostate cancer-specific gene. Urology 62 (5 Suppl. 1), 34–43 (2003).
  Article PubMed Google Scholar
• Iwakiri, J. et al. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J. Urol. 149, 783–786 (1993).
  Article CAS PubMed Google Scholar
• Meng, F. J. et al. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol. Biomarkers Prev. 11, 305–309 (2002).
  CAS PubMed Google Scholar
• van Gils, M. P. et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67, 881–887 (2007).
  Article CAS PubMed Google Scholar
• van Gils, M. P. et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 13, 939–943 (2007).
  Article CAS PubMed Google Scholar
• Groskopf, J. et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52, 1089–1095 (2006).
  Article CAS PubMed Google Scholar
• Sokoll, L. J. et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin. Chim. Acta 389, 1–6 (2008).
  Article CAS PubMed Google Scholar
• Shappell, S. B. et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73, 363–368 (2008).
  Article PubMed Google Scholar
• Marks, L. S. et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69, 532–535 (2007).
  Article PubMed Google Scholar
• Deras, I. L. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179, 1587–1592 (2008).
  Article PubMed Google Scholar
• Haese, A. et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol. 54, 1081–1088 (2008).
  Article PubMed Google Scholar
• Ankerst, D. P. et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol. 180, 1303–1308 (2008).
  Article PubMed Google Scholar
• Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
  Article CAS Google Scholar
• Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006).
  Article CAS Google Scholar
• Hessels, D. et al. Detection of TMPRSS2_–_ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103–5108 (2007).
  Article CAS PubMed Google Scholar
• Laxman, B. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645–649 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• van Gils, M. P. et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68, 1215–1222 (2008).
  Article PubMed Google Scholar
• Nakanishi, H. et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 179, 1804–1809 (2008).
  Article PubMed Google Scholar
• Whitman, E. J. et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 180, 1975–1978 (2008).
  Article PubMed Google Scholar